

Interhospital Rounds 2017

The Emerging Story of Oncofertility: From Bench to Bedside to Babies

Ontario Telemedicine Network (OTN) Live Video Feed

Locations

Mount Sinai Hospital
St. Michael's Hospital
Sunnybrook Health Sciences Centre
St. Joseph's Health Centre
Toronto East General Hospital
Norfolk General Hospital (Simcoe)
North York General Hospital
Rouge Valley Health System – Centenary
Trillium Health Partners – CVH
Trillium Health Partners – Mississauga
William Osler Health Sys – Brampton
William Osler Health Sys – Etobicoke
Scarborough Hospital – Birchmount
Humber River Hospital

OTN Live Webcast Watch Live:

<http://webcast.otn.ca/mywebcast?id=67574636>

This is an open access/public event.

Live Q and A Session

Email questions during the event to:
John.Kingdom@sinahealthsystem.ca

Ways to participate

- Live audience
- Live OTN video feed
- Live webcast (individual/group)
- Recorded - view web archive
<http://webcast.otn.ca/index/browse/?page=1&type=1> (password required for **private** gallery; search for "Interhospital" in the **public** events section)

Event Code: 67574636

To join the IHRounds network of clinical sites or receive IHR event alerts from UofT Ob/Gyn contact, obgyn.communications@utoronto.ca.



Obstetrics & Gynaecology
UNIVERSITY OF TORONTO

Sponsors



Friday, March 17th, 2017

8:00 A.M. - 9:00 A.M.

Mount Sinai Hospital, 18th Floor, Ben Sadowski Auditorium



Dr. Teresa Woodruff

is the Thomas J. Watkins Professor of Obstetrics & Gynecology, the Vice Chair of Research (OB/GYN), the Chief of the Division of Reproductive Science in Medicine, Feinberg School of Medicine, and Professor of Molecular Biosciences at the Weinberg College of Arts and Sciences at Northwestern University. She is also the Director of the Center for Reproductive Science, Founder and Director of the Women's Health Research Institute and Director of the Oncofertility Consortium. She is an internationally recognized expert in ovarian biology and, in 2006, coined the term "oncofertility" to describe the merging of two fields: oncology and fertility. Based on the pioneering science done in her lab, Dr. Woodruff was awarded a prestigious Roadmap Grant from the NIH (2007). She now heads the Oncofertility Consortium, an interdisciplinary team of biomedical and social scientist experts from across the country. She has been active in education not only at the professional level but also with high school students. To this end, she founded and directs the Oncofertility Saturday Academy (OSA), one of several high school outreach programs that engages girls in basic and medical sciences. She was awarded the Presidential Award for Excellence in Science Mentoring in an oval office ceremony from President Obama (2011). Dr. Woodruff leads a large group of scientists, postdoctoral fellows, graduate students, undergraduates, visiting scholars and technicians who together make up the Woodruff Lab. Widely recognized for her work, Woodruff holds 10 U.S. Patents, and in 2013 she was named to Time magazine's 'Most Influential Persons' list. Some of her recent awards and honors include the Society for Endocrinology Transatlantic Medal (2017), the Laureate Award from the Endocrine Society (2017), IDP Sherman Fairchild Foundation Research Innovation Challenge Award (2016), the Lay "O" Award from the Alumni Board of Olivet Nazarene University (2016) and received an honorary MD from the University of Birmingham, College of Medical, UK (2016). She is civically active and is an elected member of The Economic Club of Chicago and an elected Fellow of the American Association for the Advancement of Science. Woodruff served on the school board of the Chicago-based Young Women's Leadership Charter School, served as president of the Endocrine Society and championed the new NIH policy that mandates the use of females in fundamental research.

EDUCATIONAL OBJECTIVES

1. To provide a comprehensive overview of how cancer treatments affect the female reproductive axis.
2. Delineate the diverse fertility preservation options that are currently available or being developed for young women.
3. Describe current measures of ovarian reserve that can be used pre- and post-cancer treatment.